Genetic Technologies Ltd.
GENE
GENE was delisted on the 16th of October, 2024.
8 hedge funds and large institutions have $205K invested in Genetic Technologies Ltd. in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
10% more capital invested
Capital invested by funds: $186K → $205K (+$18.4K)
20% less funds holding
Funds holding: 10 → 8 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$52K |
| 2 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$41.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4.56K |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$142 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$25K |
| 2 |
Morgan Stanley
New York
|
-$2.44K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$516 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $70K | +$52K | +9,180 | +148% |
|
|
OMC
2
Old Mission Capital
Chicago,
Illinois
| $65.3K | +$41.7K | +7,348 | +110% |
|
|
3
Morgan Stanley
New York
| $46.7K | -$2.44K | -430 | -4% |
|
|
CA
4
Cetera Advisors
Denver,
Colorado
| $13K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $6.88K | +$4.56K | +805 | +119% |
|
|
FDCDDQ
6
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $1.86K | – | – | – |
|
7
Wells Fargo
San Francisco,
California
| $930 | – | – | – |
|
|
NA
8
NewEdge Advisors
New Orleans,
Louisiana
| $116 | +$142 | +25 | New |
|
|
9
Millennium Management
New York
| – | -$25K | -4,124 | Closed |
|
|
10
Simplex Trading
Chicago,
Illinois
| – | -$516 | -91 | Closed |
|
GENE Hedge Fund Activity: Q4 2022 in Review
8 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Genetic Technologies Ltd. (GENE) for Q4 2022, worth a combined $205K — up 9.9% from $186K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of GENE and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Susquehanna International Group, adding an estimated $52K. The largest seller was Millennium Management, exiting entirely with an estimated $25K sold.
- 8 institutional investors held Genetic Technologies Ltd. (GENE) as of Q4 2022, down from 10 in Q3 2022.
- Funds reported $205K of Genetic Technologies Ltd. stock for Q4 2022, up 9.9% quarter-over-quarter.
- 1 fund opened new Genetic Technologies Ltd. positions in Q4 2022 and 3 closed out, a net change of -2 holders.
- The largest Genetic Technologies Ltd. buyer in Q4 2022 was Susquehanna International Group, an estimated $52K added.
- The largest Genetic Technologies Ltd. seller in Q4 2022 was Millennium Management, an estimated $25K sold.
Based on aggregated 13F filings for Q4 2022.